Invesco Biotechnology & Genome ETF (PBE)

NYSE · US Equities - Industry Sector · USA

Are the companies inside PBE undervalued?

The companies inside PBE trade 5% below what we estimate they are worth. We could give a verdict on 98% of the fund's weight: 33 holdings as reported to the SEC at 31 Jul 2026.

Where the money is: 22% in companies in the buy zone, 7% about fairly valued, 69% overvalued, 3% without a verdict.

What does PBE hold?

The ten largest holdings, with our verdict on each:

How much does the PBE fee cost?

Its expense ratio is 0.59% a year: on $10,000 held flat that is $590 over 10 years and $1,180 over 20.

Browse

Other US Equities - Industry Sector ETFs